Hims and Hers Health's compounded Wegovy pill offering fuels market jitters

Feb 5 (Reuters) - Hims & Hers said it would statesman offering compounded versions of Novo Nordisk's Wegovy pill astatine an introductory terms of $49 per month.

The institution said the offering would beryllium guided by objective recommendations for personalized treatment, mirroring the attack it had taken with compounded injectable weight-loss drugs.

Shares ​of Novo and rival Eli Lilly dropped aft the motorboat announcement implicit concerns connected however companies volition support margins arsenic lower-cost alternatives emerge.

Below are immoderate reactions ‌to the announcement:

DAVID WAGNER, PORTFOLIO MANAGER AT APTUS CAPITAL ADVISORS

"Headline hazard astir GLP-1 volition beryllium astir for rather immoderate clip arsenic it feels similar an arms contention for marketplace stock and wide pricing. But, Lilly has ‌continued to amusement that they're the ascendant subordinate successful the abstraction and shares should enactment arsenic teflon during header risk, but erstwhile the shares yet get hit, similar they person today, it tends to beryllium a buying opportunity."

BRIAN MULBERRY, PORTFOLIO MANAGER AT ZACKS INVESTMENT MANAGEMENT

"The caller pill signifier of the GLP-1 is going to unfastened up the marketplace truthful importantly that some Lilly and Novo tin show beardown maturation successful revenue. Hims and Hers has grown into a ample organisation hub and it does accidental thing that they person gone with the ⁠Novo version. That said, Lilly is moving done its ain ‌direct-to-consumer model, truthful nary existent harm there."

MICHAEL NEDELCOVYCH, TD COWEN ANALYST

"The presumption quo for months present has been a compounder tin make a copycat mentation of a branded drug, truthful agelong arsenic they marque immoderate benignant of insignificant tweak that they judge oregon they reason benefits ‍specific diligent groups. And successful the lawsuit of GLP-1, the statement is arsenic elemental arsenic successful betwixt doses oregon little doses than are offered commercially, which evidently leaves the doorway beauteous wide open."

"Novo's guidance scope is beauteous wide and the debased extremity of it is beauteous low. So I uncertainty that this is the benignant of improvement that would origin them to interest that they ​didn't spell debased enough."

"For Lilly, the reaction, I think, is conscionable astir speculation arsenic to whether orforglipron could beryllium next"

MARKUS MANNS, PORTFOLIO MANAGER AT UNION INVESTMENT, A NOVO ‌AND LILLY SHAREHOLDER

"It seems amerciable (Hims move). However, it is not wide if and however agelong it volition instrumentality Novo to halt them and if the FDA is consenting to measurement in. Until this contented is resolved, it adds different level of uncertainty to the obesity concern story."

KAREN ANDERSEN, ANALYST AT MORNINGSTAR

"If Hims is allowed to proceed with this launch, I'm not definite wherefore they won't conscionable motorboat compounded orforglipron erstwhile Lilly receives support for that (expected successful the 2nd quarter), oregon truly immoderate caller drug, for that matter. Either the laws protecting branded drugs aren't wide enough, oregon they aren't being enforced, oregon both."